Asset profile
indacaterol maleate / mometasone furoate
Unknown / undisclosed
Evidence outlook · lead readout
NCT00557440 · Asthma
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT00557440: The study was randomized and quadruple-blind, used both placebo and active control, and measured the clinically relevant lung-function endpoint FEV1. Although the primary comparison favored indacaterol/mometasone over placebo and was statistically significant, the small sample of 37 participants limits the strength of the evidence.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.